Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

      home / sap-partners / cancer-centers / ut-health-san-antonio-mays-cancer-center

      Latest from Mays Cancer Center at UT Health San Antonio


      Elacestrant Shows PFS Benefit For Patients With ER+/HER2-, ESR1-Mutated Breast Cancer and Prior CDK4/6 Treatment History

      Elacestrant Shows PFS Benefit For Patients With ER+/HER2-, ESR1-Mutated Breast Cancer and Prior CDK4/6 Treatment History

      Megan Hollasch
      June 14th 2023

      Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median progression free survival of 8.61 months with elacestrant compared with 1.91 months for those given standard therapy.


      Man practicing yoga

      Yoga Encourages Antitumor Response, Boosts Quality of Life in Patients with Prostate Cancer

      Colleen Moretti
      September 16th 2021

      Yoga has a positive impact on the vagus nerve, which influences how people think, remember, and feel, and therefore can improve the mental well-being of patients with prostate cancer.


      blood cells

      Improved OS in Myelofibrosis Associated with Week 24 Transfusion Independence with Momelotinib

      Caroline Seymour
      June 28th 2021

      The phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials reported that Week 24 transfusion independence resulted in an improved overall survival for patients with myelofibrosis.

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.